In the rapidly evolving life sciences landscape, where the pursuit of innovative therapies and life-saving drugs never ceases, science and technology are increasingly playing a vital role. High-performance Computing (HPC) stands at the forefront of this technology revolution, empowering pharmaceutical and medical device enterprises, as well as research and academia, to unravel the complexities of biology, medicine, and multi-omics like never before.
HPC is no longer confined to successful pilot phases but is transitioning to wider adoption, addressing essential business needs across industries, including life sciences. The pharmaceutical industry, dealing with vast volumes of complex and heterogenous data, is an ideal sector for harnessing the benefits of HPC – particularly around intricate biological interactions, complex data analysis, and sophisticated simulations.
In this viewpoint, we study HPC’s high-potential use cases in life sciences and how pharmaceutical companies can derive success from their HPC initiatives.
Scope
Industry: life sciences
Geography: global
Contents
In this report, we explore:
HPC’s evolution, including the examination of an HPC-enabled system and the catalysts driving its adoption across industries
The current supply ecosystem, highlighting prominent pharmaceutical and medical device HPC use cases
The drivers and barriers to HPC adoption and important enterprise considerations before transitioning to HPC
A step-based adoption roadmap for life sciences enterprises and a peek into HPC’s future in life sciences
